KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aceptableAviso de calidad de datosSin actividad de trading
Datos del 9 sept 2026, 10:40 UTC · política pm-quality-3
Probabilidad implícita actual
Above 1025000 0%Líder entre 5 opciones
Calidad del mercado
39 / 100
Baja calidadVolumen 24h
—
Liquidez
—
Liquidez desconocidaSpread
4.0 pt
Spread moderadoDatos de mercado
Actualizado hace 7 minutos
13 ago 26, 2:25 UTC5 mar 27, 5:00 UTC
Tendencias
0%
0%
0%
0%
0%
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Reglas
If Natera, Inc. reports the named outcome tests processed in Q3 2026, then the market resolves to Yes.
Liquida mediante:Fiscal.ai
- Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the underlying company.
- All trademarks, logos, and brand names are the property of their respective owners.
Mercados abiertos
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Volumen total
- 15,6 M €
- Volumen 24h
- 20,3 mil €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+0.6pt4%
- Volumen total
- 1,6 M €
- Volumen 24h
- 8 mil €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+4.0pt65%
- September41%
- June28%
- Volumen total
- 84,1 mil €
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volumen total
- 652,6 mil €
- Volumen 24h
- 3,4 mil €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-4.0pt58%
+2 resultados más
- Volumen total
- 865,4 mil €
- Volumen 24h
- 3 mil €
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Volumen total
- 915,2 mil €
- Volumen 24h
- 1,2 mil €
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Measles cases in U.S. in 2026?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de Natera tests processed in Q3?
- Kalshi cotiza Above 1025000 al 0% a fecha de 9 de septiembre de 2026.
- ¿Cuándo se resuelve Natera tests processed in Q3?
- Está previsto que Natera tests processed in Q3 se resuelva el 5 de marzo de 2027.
- ¿Cómo se liquida Natera tests processed in Q3?
- Kalshi liquida este mercado del siguiente modo: If Natera, Inc. reports the named outcome tests processed in Q3 2026, then the market resolves to Yes.